ThromboGenics to Present Results of Second Phase III Trial of Microplasmin at the 28th Annual Meeting of the American Society of Retina Specialists (ASRS) and the 10th EURETINA Congress

Thursday, July 1, 2010 Research News
Email Print This Page Comment bookmark
Font : A-A+

LEUVEN, Belgium, July 1, 2010 ThromboGenics NV(Euronext Brussels: THR), a biopharmaceutical company focused on thediscovery and development of innovative treatments for eye disease, announcesthat data from the second Phase III trial of microplasmin (TG-MV-007) for thenon-surgical treatment of vitreomacular adhesion (VMA), are to be presentedat the 28th Annual Meeting of the American Society of Retina Specialists(ASRS) and the 10th EURETINA Congress. Positive data from the first Phase IIItrial of microplasmin (TG-MV-006), previously disclosed at the WorldOphthalmology Congress in June, will also be presented at both conferences.

The Annual Meeting of ASRS is the largest gathering of retina specialistsin the United States. The acceptance of these two presentations demonstratesthe growing interest amongst the retina community in microplasmin's potentialto offer an effective, convenient, non-surgical treatment option for a rangeof retinal diseases.

The EURETINA congress is one of the largest gatherings of retinaspecialists in Europe and an excellent platform to raise awareness of thepotential of microplasmin.

The full results of the TG-MV-006 study were presented at the WorldOphthalmology Congress in Berlin on 6 June 2010 by Dr. Matthew Benz of TheMethodist Hospital, Texas, USA. Details of these results can be found in thepress release dated 6 June 2010, available at

Notes to Editors

About Focal Vitreomacular Adhesion (VMA)

Focal vitreomacular adhesion is a condition in which the vitreous gel, inthe center of the eye, has an abnormally strong adhesion to the macula, thecenter of the retina at the back of the eye. Vitreomacular adhesion isthought to play a key role in numerous back of the eye conditions, such asmacular hole and some forms of macular edema. Vitreomacular adhesion is alsoassociated with a poorer prognosis in certain major eye conditions, includingDiabetic Retinopathy and Age-related Macular Degeneration (AMD).

The MIVI-TRUST Program

The microplasmin Phase III program, referred to as MIVI-TRUST(Microplasmin for IntraVitreous Injection-Traction Release without SurgicalTreatment), consists of two multi-center, randomized, placebo-controlled,double-masked trials. These trials are designed to evaluate 125μg ofmicroplasmin versus placebo in the treatment of patients with symptomaticfocal vitreomacular adhesion (VMA). The MIVI-TRUST program is the largestinterventional clinical program ever performed to specifically evaluate thevitreoretinal interface in patients with retinal disorders. In total, over650 patients were enrolled in these trials, which were held across 90 centersin 7 countries.

The primary endpoint of both trials is the non-surgical resolution offocal vitreomacular adhesion one month after a single injection ofmicroplasmin. This endpoint is being measured and recorded using opticalcoherence tomography (OCT), the standard method of assessment for thiscondition, which provides images that can clearly show the separation of thevitreous from the retina.

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery anddevelopment of innovative medicines for the treatment of eye disease. TheCompany's lead product microplasmin has completed its first Phase IIIclinical trial for the non-surgical treatment of back of the eye diseases.Microplasmin is also being evaluated in Phase II clinical development foradditional vitreoretinal conditions. In addition, ThromboGenics is developingnovel antibody therapeutics in collaboration with BioInvent International;these include TB-402 (anti-Factor VIII), a long acting anti-coagulant inPhase II, and TB-403 (anti-PlGF) in Phase I for cancer in partnership withRoche.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listedon Eurolist by Euronext Brussels under the symbol THR. More information isavailable at

Important information about forward-looking statements

Certain statements in this press release may be considered"forward-looking". Such forward-looking statements are based on currentexpectations, and, accordingly, entail and are influenced by various risksand uncertainties. The Company therefore cannot provide any assurance thatsuch forward-looking statements will materialize and does not assume anobligation to update or revise any forward-looking statement, whether as aresult of new information, future events or any other reason. Additionalinformation concerning risks and uncertainties affecting the business andother factors that could cause actual results to differ materially from anyforward-looking statement is contained in the Company's Annual Report.The schedule of presentations for both upcoming conferences is as follows: ASRS (American Society of Retina Specialists) Congress to be held 28 August - 1 September in Vancouver, BC, Canada - August 31: Dr. J. Michael Jumper of West Coast Retina and U.C. San Francisco (California, USA) will present results from the TG-MV-007 trial. - August 31: Dr. Kirk Packo of Rush University Medical Center, Chicago, Illinois, USA, will present data from the TG-MV-006 trial.

SOURCE ThromboGenics NV

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store